OTCMKTS:NICXF

Nicox Stock Forecast, Price & News

$5.10

0.00 (0.00 %)

(As of 06/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$5.10

▼

$5.10

50-Day Range

$5.08

▼

$5.15

52-Week Range

$4.36

▼

$6.46

VolumeN/A

Average Volume656 shs

Market Capitalization$170.70 million

P/E RatioN/A

Dividend YieldN/A

Beta0.75

30 days | 90 days | 365 days | Advanced Chart

Receive NICXF News and Ratings via Email

Sign-up to receive the latest news and ratings for Nicox and its competitors with MarketBeat's FREE daily newsletter.

About Nicox

Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.

Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021
June 23, 2021 | finance.yahoo.com

Nicox's NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021
June 23, 2021 | benzinga.com

Head-To-Head Comparison: Nicox (OTCMKTS:NICXF) & Eisai (OTCMKTS:ESALY)
June 21, 2021 | americanbankingnews.com

Nicox (OTCMKTS:NICXF) Stock Price Up 0.4%
June 3, 2021 | americanbankingnews.com

Number of voting rights as of May 31, 2021
June 1, 2021 | finance.yahoo.com

Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial
June 1, 2021 | finance.yahoo.com

Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar
May 4, 2021 | markets.businessinsider.com

Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar
May 4, 2021 | finance.yahoo.com

Number of voting rights as of April 30, 2021
May 3, 2021 | finance.yahoo.com

Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod
April 30, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NICXF
Previous SymbolNASDAQ:NICXF
CUSIPN/A
CIKN/A
Webwww.nicox.com
Phone33-4-97-24-53-00
Employees34
Year FoundedN/A

Sales & Book Value

Annual Sales$9.25 million
Price / Sales18.45
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.14 per share
Price / Book1.23

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares33,470,000
Market Cap$170.70 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.36 out of 5 stars

Medical Sector

1836th out of 2,105 stocks

Private Households Industry

357th out of 381 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Nicox.

1.8 Community Rank

Outperform Votes
Nicox has received 102 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Nicox has received 174 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Nicox has received 63.04% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Nicox and other stocks. Vote “Outperform” if you believe NICXF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NICXF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Nicox does not currently pay a dividend.
Dividend Growth
Nicox does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nicox insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Nicox are expected to decrease in the coming year, from ($0.83) to ($1.09) per share.
Price to Book Value per Share Ratio
Nicox has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Nicox (OTCMKTS:NICXF) Frequently Asked Questions

What stocks does MarketBeat like better than Nicox?

Wall Street analysts have given Nicox a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nicox wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Nicox's stock been impacted by COVID-19?

Nicox's stock was trading at $4.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NICXF shares have increased by 17.2% and is now trading at $5.10.
View which stocks have been most impacted by COVID-19.

Who are Nicox's key executives?

Nicox's management team includes the following people:

Mr. Michele Garufi, Co-Founder, Chairman & CEO (Age 67, Pay $611.35k)
Ms. Sandrine Gestin, VP of Fin. (Age 54)
Ms. Emmanuelle Pierry, Gen. Counsel & Head of Legal (Age 52)
Dr. Gavin Spencer, Exec. VP, Chief Bus. Officer & Head of Corp. Devel. (Age 51)
Dr. Ramesh Krishnamoorthy, Sr. Director and Head of Late Stage CMC & Quality Control
Dr. Jose Boyer, Interim Head of R&D
Dr. Ennio Ongini Ph.D., Consultant

Who are some of Nicox's key competitors?

Some companies that are related to Nicox include Petrofac (POFCY), OPHIR ENERGY PL/ADR (OPHRY), Superdry (SEPGY), Absolute Software (ALSWF), PayPoint (PYPTF), Datatec (DTTLY), CTT - Correios De Portugal (CTTPY), SThree (STREF), IQE (IQEPF), Eagle Point Credit (ECC), EnQuest (ENQUF), Purplebricks Group (PRPPF), Enthusiast Gaming (EGLX), The Restaurant Group (RSTGF) and Foxtons Group (FXTGY).
View all of NICXF's competitors.

What is Nicox's stock symbol?

Nicox trades on the OTCMKTS under the ticker symbol "NICXF."

How do I buy shares of Nicox?

Shares of NICXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nicox's stock price today?

One share of NICXF stock can currently be purchased for approximately $5.10.

How much money does Nicox make?

Nicox has a market capitalization of $170.70 million and generates $9.25 million in revenue each year.

How many employees does Nicox have?

Nicox employs 34 workers across the globe.

What is Nicox's official website?

The official website for Nicox is www.nicox.com.

Where are Nicox's headquarters?

Nicox is headquartered at Drakkar 2 - Batiment D 2405 route des Dolines - CS 10313 Sophia Antipolis Cedex, Valbonne I0, 06560.

How can I contact Nicox?

Nicox's mailing address is Drakkar 2 - Batiment D 2405 route des Dolines - CS 10313 Sophia Antipolis Cedex, Valbonne I0, 06560. The company can be reached via phone at 33-4-97-24-53-00.

This page was last updated on 6/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Nicox Stock Forecast, Price & News

About Nicox

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

1.8 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

Dividend Yield

Dividend Growth